Asmanex HFA is a prescription medication used for the maintenance treatment of asthma in patients 12 years of age and older. It is a corticosteroid that works by reducing inflammation in the airways.
What is the active ingredient in Asmanex HFA?
The active ingredient in Asmanex HFA is mometasone furoate [1]. Mometasone furoate is an inhaled corticosteroid (ICS) that helps to control inflammation in the lungs.
How does Asmanex HFA work to treat asthma?
Asmanex HFA is an inhaled corticosteroid that reduces inflammation in the airways [1]. By decreasing airway inflammation, it helps to prevent asthma symptoms such as wheezing, shortness of breath, chest tightness, and coughing. It is intended for long-term use to manage persistent asthma.
How is Asmanex HFA administered?
Asmanex HFA is administered through an inhaler device, which delivers the medication directly into the lungs [1]. The specific dosage and frequency of use are determined by a healthcare provider.
What are the potential side effects of Asmanex HFA?
Common side effects of Asmanex HFA can include headache, oral candidiasis (thrush), and upper respiratory tract infections [1]. More serious side effects, though less common, can occur. Patients should discuss potential risks with their doctor.
What is the difference between Asmanex HFA and other asthma inhalers?
Asmanex HFA is a corticosteroid inhaler, which is a type of controller medication used for long-term asthma management. It differs from rescue inhalers, such as short-acting beta-agonists, which are used to provide quick relief from acute asthma symptoms. Asmanex HFA addresses the underlying inflammation, while rescue inhalers open up the airways temporarily.
When does Asmanex HFA patent protection expire?
The patent expiration dates for Asmanex HFA, and its active ingredient mometasone furoate, are tracked by services like DrugPatentWatch.com [2]. Specific patent timelines can be complex due to multiple patents covering different aspects of the drug and its formulation. Information on patent status and potential generic entry can be found through patent databases.